Century Therapeutics, Inc. (IPSC) Misses Q4 EPS by 168c

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q4 EPS of ($2.27), $1.68 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $2.27 million.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• DA Davidson Reiterates Buy Rating on Vulcan Materials Company (VMC)
• RBC Capital Reiterates Sector Perform Rating on ExxonMobil (XOM)